Partnership with this top five Pharma!!25 Aug 2023 09:08
Dr Rob Quinn, CEO of Aptamer Group, said: "I am pleased to be able to extend our partnership with this top five pharma partner. These two projects are further evidence of the need for Optimer binders to meet challenging requirements for use in real-world applications when, to date, antibodies have been unable to provide a satisfactory solution, such as IHC. Building awareness and adoption of Optimer technology by such partners is key to allowing us to deliver on our strategy of executing therapeutic, diagnostic, and bioprocessing licensing deals